-
Something wrong with this record ?
Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?
M. Bareš, I. Rektorová, R. Jech, K. Farníková, J. Roth, E. Růžička, P. Kaňovský, I. Rektor, T. Pavlík, L. Uhlířová, J. Vydlák
Language English Country Austria
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adult MeSH
- Levodopa therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Parkinson Disease drug therapy MeSH
- Disability Evaluation MeSH
- Surveys and Questionnaires MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Drug Tolerance MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson's disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists' assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0-2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists' assessment of wearing-off symptoms and PD patients' subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.
Department of NeurologyFaculty of Medicine Palacky University
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12034926
- 003
- CZ-PrNML
- 005
- 20160805154008.0
- 007
- ta
- 008
- 121023s2012 au f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00702-011-0683-9 $2 doi
- 035 __
- $a (PubMed)21769622
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a au
- 100 1_
- $a Bareš, Martin, $d 1968- $7 xx0022580 $u Movement Disorders Centre Brno and First Department of Neurology, Faculty of Medicine Masaryk University Brno, St. Anne's Hospital Pekarska 53, 656 91 Brno, Czech Republic. martin.bares@fnusa.cz
- 245 10
- $a Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease? / $c M. Bareš, I. Rektorová, R. Jech, K. Farníková, J. Roth, E. Růžička, P. Kaňovský, I. Rektor, T. Pavlík, L. Uhlířová, J. Vydlák
- 520 9_
- $a EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson's disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists' assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0-2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists' assessment of wearing-off symptoms and PD patients' subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a posuzování pracovní neschopnosti $7 D004185
- 650 _2
- $a tolerance léku $7 D004361
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a levodopa $x terapeutické užití $7 D007980
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a Parkinsonova nemoc $x farmakoterapie $7 D010300
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rektorová, Irena, $d 1969- $7 ola2005284393 $u Movement Disorders Centre Brno and First Department of NeurologyFaculty of Medicine Masaryk University Brno
- 700 1_
- $a Jech, Robert, $d 1969- $7 xx0082225 $u Department of Neurology, First Faculty of MedicineCharles University in Prague and General University Hospital in Prague
- 700 1_
- $a Farníková, Kateřina $7 xx0134543 $u Department of NeurologyFaculty of Medicine Palacky University
- 700 1_
- $a Roth, Jan, $d 1961- $7 jo20000074063 $u Department of Neurology, First Faculty of MedicineCharles University in Prague and General University Hospital in Prague
- 700 1_
- $a Růžička, Evžen, $d 1957- $7 jo20000074065 $u Department of Neurology, First Faculty of MedicineCharles University in Prague and General University Hospital in Prague
- 700 1_
- $a Kaňovský, Petr, $d 1961- $7 jn20000620150 $u Department of NeurologyFaculty of Medicine Palacky University
- 700 1_
- $a Rektor, Ivan, $d 1948- $7 nlk19990073773 $u Movement Disorders Centre Brno and First Department of NeurologyFaculty of Medicine Masaryk University Brno
- 700 1_
- $a Pavlík, Tomáš $7 xx0093293 $u Institute of Biostatistics and AnalysesMasaryk University
- 700 1_
- $a Uhlířová, Leona $u Novartis s.r.o
- 700 1_
- $a Vydlák, Jaroslav $u Novartis s.r.o
- 773 0_
- $w MED00010058 $t Journal of neural transmission $x 0300-9564 $g Roč. 119, č. 3 (2012), s. 373-380
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21769622 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20121023 $b ABA008
- 991 __
- $a 20160805154243 $b ABA008
- 999 __
- $a ok $b bmc $g 956936 $s 792423
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 119 $c 3 $d 373-380 $i 0300-9564 $m Journal of neural transmission $n J Neural Transm $x MED00010058
- LZP __
- $b NLK112 $a Pubmed-20121023
